TY - JOUR
T1 - Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis
T2 - A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group
AU - Michinoku Tocilizumab Study Group
AU - Hirabayashi, Yasuhiko
AU - Munakata, Yasuhiko
AU - Miyata, Masayuki
AU - Urata, Yukitomo
AU - Saito, Koichi
AU - Okuno, Hiroshi
AU - Yoshida, Masaaki
AU - Kodera, Takao
AU - Watanabe, Ryu
AU - Miyamoto, Seiya
AU - Ishii, Tomonori
AU - Nakazawa, Shigeshi
AU - Takemori, Hiromitsu
AU - Ando, Takanobu
AU - Kanno, Takashi
AU - Komagamine, Masataka
AU - Kato, Ichiro
AU - Takahashi, Yuichi
AU - Komatsuda, Atsushi
AU - Endo, Kojiro
AU - Murai, Chihiro
AU - Takakubo, Yuya
AU - Miura, Takao
AU - Sato, Yukio
AU - Ichikawa, Kazunobu
AU - Konta, Tsuneo
AU - Chiba, Noriyuki
AU - Muryoi, Tai
AU - Kobayashi, Hiroko
AU - Fujii, Hiroshi
AU - Sekiguchi, Yukio
AU - Hatakeyama, Akira
AU - Ogura, Ken
AU - Sakuraba, Hirotake
AU - Asano, Tomoyuki
AU - Kanazawa, Hiroshi
AU - Suzuki, Eiji
AU - Takasaki, Satoshi
AU - Asakura, Kenichi
AU - Sugisaki, Kota
AU - Suzuki, Yoko
AU - Takagi, Michiaki
AU - Nakayama, Takahiro
AU - Watanabe, Hiroshi
AU - Miura, Keiki
AU - Mori, Yu
AU - Harigae, Hideo
AU - Ichinohasama, Ryo
AU - Itoi, Eiji
AU - Yamaya, Seiji
N1 - Publisher Copyright:
© 2016 Japan College of Rheumatology.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Objective: To evaluate the clinical and structural efficacy of tocilizumab (TCZ) during its long-term administration in patients with rheumatoid arthritis (RA). Methods: In total, 693 patients with RA who started TCZ therapy were followed for 3 years. Clinical efficacy was evaluated by DAS28-ESR and Boolean remission rates in 544 patients. Joint damage was assessed by calculating the modified total Sharp score (mTSS) in 50 patients. Results: When the reason for discontinuation was limited to inadequate response or adverse events, the 1-, 2-, and 3-year continuation rates were 84.0%, 76.8%, and 72.2%, respectively. The mean DAS28-ESR was initially 5.1 and decreased to 2.5 at 6 months and to 2.2 at 36 months. The Boolean remission rate was initially 0.9% and increased to 21.7% at 6 months and to 32.2% at 36 months. The structural remission rates (ΔmTSS/year ≤ 0.5) were 68.8%, 78.6%, and 88.9% within the first, second, and third years, respectively. The structural remission rate at 3 years (ΔmTSS ≤ 1.5) was 66.0%, and earlier achievement of swollen joint count (SJC) of 1 or less resulted in better outcomes. Conclusions: TCZ was highly efficacious, and bone destruction was strongly prevented. SJC was an easy-to-use indicator of joint destruction.
AB - Objective: To evaluate the clinical and structural efficacy of tocilizumab (TCZ) during its long-term administration in patients with rheumatoid arthritis (RA). Methods: In total, 693 patients with RA who started TCZ therapy were followed for 3 years. Clinical efficacy was evaluated by DAS28-ESR and Boolean remission rates in 544 patients. Joint damage was assessed by calculating the modified total Sharp score (mTSS) in 50 patients. Results: When the reason for discontinuation was limited to inadequate response or adverse events, the 1-, 2-, and 3-year continuation rates were 84.0%, 76.8%, and 72.2%, respectively. The mean DAS28-ESR was initially 5.1 and decreased to 2.5 at 6 months and to 2.2 at 36 months. The Boolean remission rate was initially 0.9% and increased to 21.7% at 6 months and to 32.2% at 36 months. The structural remission rates (ΔmTSS/year ≤ 0.5) were 68.8%, 78.6%, and 88.9% within the first, second, and third years, respectively. The structural remission rate at 3 years (ΔmTSS ≤ 1.5) was 66.0%, and earlier achievement of swollen joint count (SJC) of 1 or less resulted in better outcomes. Conclusions: TCZ was highly efficacious, and bone destruction was strongly prevented. SJC was an easy-to-use indicator of joint destruction.
KW - Joint destruction
KW - Long-term administration
KW - Real clinical practice
KW - Rheumatoid arthritis
KW - Tocilizumab
UR - http://www.scopus.com/inward/record.url?scp=84964507319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964507319&partnerID=8YFLogxK
U2 - 10.3109/14397595.2016.1160991
DO - 10.3109/14397595.2016.1160991
M3 - Article
C2 - 26934116
AN - SCOPUS:84964507319
VL - 26
SP - 828
EP - 835
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 6
ER -